Neoadjuvant chemotherapy with S-1 and oxaliplatin (SOX) may be a suitable treatment measure for patients with advanced gastric or esophagogastric junction adenocarcinoma, according to the RESONANCE* trial presented at ASCO GI 2020.
The interest in healthcare and medicine is evident from companies in fields unrelated to healthcare venturing into the scene. With this interest is the boom of healthcare facilities, both clinics and hospitals, being set up in the country. As of end 2017, Malaysia counted 200 private hospitals with 14,799 beds. [https://www.export.gov/article?id=Malaysia-Healthcare, Accessed on 18 November]
The recent launch of Sunway Medical Centre Velocity (SMCV) coincides with the boom of hospitals established in the country. However, its founding should not be seen as jumping on the bandwagon. Rather, the hospital is a carefully planned and executed venture. MIMS spoke to SMCV’s Chief Executive Officer, Wilson Choo, to get his insights on the establishment of SMCV and his vision for SMCV in the short and long term.
In an exclusive interview with MIMS, Kenny Lim, Chief Information Technology Officer of Bumrungrad International Hospital shared his views on how the hospital has continued to improve its services to patients with particular emphasis on the use of clinical decisions support tools.
The humanized monoclonal antibody mirikizumab appears to reduce bowel movement urgency among patients with moderate to severely active ulcerative colitis (UC), according to a study presented at the Crohn’s and Colitis Congress 2020.
Children with inflammatory bowel disease (IBD) do not appear to have an elevated risk of lymphoma following treatment with anti-tumour necrosis factor (TNF) agents, according to a study presented at the recent Crohn’s and Colitis Congress 2020.
Adding pegilodecakin, a pegylated form of interleukin-10 (IL-10), to second-line FOLFOX chemotherapy does not significantly improve overall survival (OS) or other outcomes in patients with advanced pancreatic ductal adenocarcinoma (PDAC) as compared with FOLFOX alone, results of the phase III SEQUOIA trial have shown.
Children with ulcerative colitis (UC) who undergo a proctocolectomy may have an increased risk of readmission to hospital 30 days after their initial hospital admission, according to a retrospective cohort study presented at the recent Crohn’s and Colitis Congress 2020.